40665-93-8 Usage
Uses
Used in Ophthalmology:
16-(3-chlorophenoxy)-17,18,19,20-tetranorprostaglandin F2 alpha is used as a therapeutic agent for glaucoma treatment, aiming to reduce intraocular pressure. Its ability to selectively activate the prostanoid FP receptor may provide a targeted approach to managing this condition, potentially improving patient outcomes and reducing the risk of vision loss.
Used in Reproductive Physiology Research:
In the field of reproductive physiology, 16-(3-chlorophenoxy)-17,18,19,20-tetranorprostaglandin F2 alpha is used as a research tool to study its role in inducing luteolysis in the ovaries. Understanding its mechanism of action may contribute to the development of new treatments for conditions related to the menstrual cycle, fertility, and hormonal imbalances.
Used in Pharmaceutical Development:
16-(3-chlorophenoxy)-17,18,19,20-tetranorprostaglandin F2 alpha is utilized as a lead compound in the development of new pharmaceuticals targeting the prostanoid FP receptor. Its selective agonist activity may pave the way for the creation of more effective and safer medications for a range of medical conditions, including those related to inflammation, smooth muscle function, and blood flow regulation.
Check Digit Verification of cas no
The CAS Registry Mumber 40665-93-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,6,6 and 5 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 40665-93:
(7*4)+(6*0)+(5*6)+(4*6)+(3*5)+(2*9)+(1*3)=118
118 % 10 = 8
So 40665-93-8 is a valid CAS Registry Number.
InChI:InChI=1/C22H29ClO6/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28)/b3-1-,11-10+/t16?,18-,19-,20+,21+/m1/s1
40665-93-8Relevant academic research and scientific papers
Synthesis of (±) travoprost and its analogs
Mudduluru, Harikrishna,Hindupur, Rama M.,Dubey, Pramod K.,Madhavaram, Shankar,Tatini, Lakshmikumar,Subbaraju, Gottumukkala V.
experimental part, p. 234 - 241 (2012/04/18)
A new synthetic approach for the antiglaucoma agent, travoprost (1) has been developed in four steps from key intermediate (2). Key transformations include Horner-Wadsworth-Emmons reaction and separation of diastereomers to obtain (±) travoprost (1) and its analogs.
PROSTANOIDS. XIX. THE SYNTHESIS OF 14C-LABELED CLOPROSTENOL
Miftakhov, M. S.,Vostrikov, N. S.,Kuznetsov, O. M.,Kuvatov, Yu. G.,Murinov, Yu. I.,Tolstikov, G. A.
, p. 1072 - 1075 (2007/10/02)
A 1:3400 mixture of 2-14C-labelled methyl bromoacetate with the nonradioactive ester gave labelled dimethoxy-2-oxo-3-(m-chlorophenoxy)phosphonate which was used for the synthesis of 16-14C-labelled cloprostenol by the Corey strategy.
